Cagrilintide
Novo Nordisk's long-acting amylin analogue for weight management — potent when combined, modest as monotherapy.
Verdict — C · Emerging / Mixed
Amylin analogue with a clean mechanistic rationale and reasonable safety in trials, but the real story is in combination. Standalone approval is unlikely; wait for CagriSema data and a licensed supply path.
Overview
Cagrilintide is a long-acting amylin analogue designed for weekly subcutaneous dosing, studied both as monotherapy and in combination with semaglutide (CagriSema). Phase-2 monotherapy data showed approximately 10-11% weight loss, while the combination shows markedly greater effect. It has not received regulatory approval as a standalone compound, and no verified consumer supply exists.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.